Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H14N7O5S4.Na |
| Molecular Weight | 535.576 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=CN=NS3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4
InChI
InChIKey=BCMSQWPLFBUUKW-IXLPVNPSSA-M
InChI=1S/C16H15N7O5S4.Na/c1-28-21-9(7-5-31-16(17)19-7)12(24)20-10-13(25)23-11(15(26)27)6(4-30-14(10)23)3-29-8-2-18-22-32-8;/h2,5,10,14H,3-4H2,1H3,(H2,17,19)(H,20,24)(H,26,27);/q;+1/p-1/b21-9-;/t10-,14-;/m1./s1
| Molecular Formula | C16H14N7O5S4 |
| Molecular Weight | 512.586 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/3613097Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/3322588
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613097
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/3322588
Cefuzoname (CZON, L-105) is a second-generation cephalosporin antibiotic, has broad spectrum on Gram-positive or -negative bacteria and may also be effective against Staphylococcus aureus against which third generation cephalosporins are largely ineffective.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3530123
Curator's Comment: CNS penetrant in rabbits and humans http://www.ncbi.nlm.nih.gov/pubmed/3613085
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Klebsiella pneumoniae growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613094 |
|||
Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613094 |
|||
Target ID: map00550 Sources: http://www.kegg.jp/dbget-bin/www_bget?dr:D03432 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Clinical studies on cefuzonam for acute peritonitis due to perforated appendicitis. Tissue concentration and clinical efficacy]. | 1991-09 |
|
| Bone cement not weakened by cefuzonam powder. | 1991-06 |
|
| [Clinical evaluation of cefuzonam (CZON) for bacterial pneumonia and lung abscess: comparative study with cefotiam (CTM)]. | 1991-04 |
|
| [Fundamental and clinical studies on cefuzoname in the pediatric field]. | 1987-04 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1960860
Cefuzonam in a dose of 1 g was administered by intravenous bolus injection or intravenous drip infusion for 60 minutes.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3204654
Curator's Comment: The MIC80's against Serratia marcescens and Enterobacter aerogenes were both 6.25 ug/ml, and that against Pseudomonas aeruginosa was 100 ug/ml. The MIC80's against Staphy-lococcus epidermidis were 25 and 6.25 ug/ml, respectively. Approximately 70% of strains of S. aureus were inhibited at concentrations less than 1.56 ug/ml.
The MIC80's of cefuzonam against Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Haemophilus influenzae and Citrobacter spp. were less than 0.20 ug/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:16:40 GMT 2025
by
admin
on
Mon Mar 31 19:16:40 GMT 2025
|
| Record UNII |
6SOU25L22C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Mon Mar 31 19:16:40 GMT 2025 , Edited by admin on Mon Mar 31 19:16:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40231634
Created by
admin on Mon Mar 31 19:16:40 GMT 2025 , Edited by admin on Mon Mar 31 19:16:40 GMT 2025
|
PRIMARY | |||
|
SUB01141MIG
Created by
admin on Mon Mar 31 19:16:40 GMT 2025 , Edited by admin on Mon Mar 31 19:16:40 GMT 2025
|
PRIMARY | |||
|
23663965
Created by
admin on Mon Mar 31 19:16:40 GMT 2025 , Edited by admin on Mon Mar 31 19:16:40 GMT 2025
|
PRIMARY | |||
|
6SOU25L22C
Created by
admin on Mon Mar 31 19:16:40 GMT 2025 , Edited by admin on Mon Mar 31 19:16:40 GMT 2025
|
PRIMARY | |||
|
100000084685
Created by
admin on Mon Mar 31 19:16:40 GMT 2025 , Edited by admin on Mon Mar 31 19:16:40 GMT 2025
|
PRIMARY | |||
|
C98232
Created by
admin on Mon Mar 31 19:16:40 GMT 2025 , Edited by admin on Mon Mar 31 19:16:40 GMT 2025
|
PRIMARY | |||
|
82219-81-6
Created by
admin on Mon Mar 31 19:16:40 GMT 2025 , Edited by admin on Mon Mar 31 19:16:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL1689069
Created by
admin on Mon Mar 31 19:16:40 GMT 2025 , Edited by admin on Mon Mar 31 19:16:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |